Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

sevelamer

Sanofi reception

Sanofi plans LixiLan filings after positive phase III trial

Combination drug could cause dynamic shift in diabetes treament

Teva Pharma logo

Teva rolls out first migraine patch in US

Delivers alternative treatment option for migraine sufferers

Sanofi and Google partner on digital health in diabetes

Aimto develop new patient tools by harnessing data and miniaturised tech

Sanofi reception

Sanofi and Evotec to work together on diabetes and cancer

Willfocus on beta cell-modulating diabetes treatments and immuno-oncology therapies

Sanofi reception

Sanofi keeps Toujeo price level with Lantus in UK

French firm hoping to maintain market share with its next-gen insulin product

Teva Pharma logo

Teva takes controlling stake in genomics specialist

World’s largest generics firm takes deeper steps into patented medicines development

- PMLiVE

Pfizer links with Synthon on generic Copaxone

US giant looking to grab a share of the copycat market for the MS drug

Boehringer Ingelheim headquarters

Hikma pays $2.6bn for Boehringer’s US generics unit

Follows Teva’s $40.5bn purchase of Allgeran’s generics business earlier this week

Sanofi reception

Sanofi and Regeneron extend partnership to cancer

Sanofi will pay more than $2bn to the firm for immunotherapy research

- PMLiVE

Teva buys Allergan generics unit for $40.5bn

Will now drop its six-month pursuit of Mylan

- PMLiVE

Sanofi’s cholesterol drug Praluent backed for European approval

CHMPdecision puts firm on-course to catch up with Amgen's Repatha

- PMLiVE

FDA approves four new medicines across multiple areas

Sanofi/Regeneron, BMS, AbbVie and Novartis all chalk up major approvals

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links